Beacon Pharmaceuticals Ltd. (Beacon)
Beacon Pharmaceuticals Ltd., established in 2001, is currently the largest and most technologically advanced manufacturer of anti-cancer and antiviral drugs in Bangladesh. It is also one of the fastest-growing leading pharmaceutical companies in the country.
Beacon’s technical team is supported by renowned European consultancy firms. Its facilities are built to strict EU standards, equipped with the latest pharmaceutical technologies from Europe, and furnished with cutting-edge research equipment. These facilities fully comply with FDA (USA), MHRA (UK), TGA (Australia), and WHO GMP standards, making Beacon the only pharmaceutical company in South Asia built to EU technical specifications. The company integrates research and development, generic drug manufacturing, sales, and after-sales service into one publicly listed entity. All production is strictly in line with GMP standards, and drug quality adheres to the European, British, and U.S. pharmacopoeia.
Beacon takes full advantage of Bangladesh’s compulsory patent licensing system, in line with the WTO’s waiver for pharmaceutical patent protection in Least Developed Countries (LDCs). The company has produced over 200 new drugs, including 65 anti-cancer drugs, many of which are generic versions of global first-in-class therapies. Beacon introduces 20+ newly developed international drugs annually, leveraging a strong R&D team to launch global first generics, drawing significant attention in the international pharmaceutical community.
While meeting the domestic demand in Bangladesh, Beacon also exports to more than 120 countries and regions across Asia, Africa, Europe, and Latin America. Its products are included in the procurement lists of major humanitarian organizations, such as UNICEF and Médecins Sans Frontières (Doctors Without Borders).
Beacon is a publicly listed, well-managed pharmaceutical company, listed on the main boards of both the Dhaka and Chittagong Stock Exchanges—the only pharmaceutical company in Bangladesh to do so. It employs over 2,000 staff across all departments.
Milestones in Beacon's Development
🔹 2006 – Official Establishment
-
Beacon was founded with a focus on the high-end pharmaceutical market, especially oncology products.
-
Built modern GMP-compliant facilities, equipped with advanced European machinery.
🔹 2007–2010 – Rapid Product Line Expansion
-
Began production of oral solid dosage forms, injectables, and antibiotics.
-
Initiated oncology drug research, building technical capabilities in the field.
🔹 2011 – First Oncology Drug Launched
-
Launched its first targeted anti-cancer drug, a generic version of Sorafenib.
-
Established a leading position in the domestic market and began exporting cancer drugs.
🔹 2012–2015 – International Expansion
-
Became the first Bangladeshi pharmaceutical company to export oncology products overseas.
-
Obtained international certifications including PIC/S, ISO, and WHO GMP.
-
Entered markets in the Middle East, Africa, and Southeast Asia, and began partnerships with global distributors.
🔹 2016–2018 – Targeted Therapy and Biosimilars
-
Released new targeted therapies, including generic Erlotinib and Imatinib.
-
Began developing biosimilars, entering the field of immuno-oncology and monoclonal antibodies.
🔹 2019–2023 – Technological Transformation and Global Outreach
-
Established a dedicated R&D division, focusing on biologic oncology drugs and complex formulations such as liposomes and controlled-release systems.
-
Launched a research-use CAR-T technology platform.
-
Joined global pharmaceutical innovation alliances, collaborating with CROs and tech companies.
🔹 2024–Present – Global Market Focus & Advanced Formulations
-
Continued expanding into South America, Latin America, Asia, and Africa.
-
Developed nanotechnology-based drugs and ADC (Antibody-Drug Conjugate) generics.
-
Emerged as one of the most prominent exporters of oncology drugs from Bangladesh.
